Serologic immunity was 39.5% for hepatitis A and 27.1% for hepatitis B in a nationally representative study of US adults, with gaps across high-risk groups.
In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...
A large US cohort study examined hepatitis B virus (HBV) monitoring practices and the risk of HBV reactivation and hepatitis flares during interruptions of tenofovir-containing antiretroviral therapy among...
On Friday, the Advisory Committee on Immunization Practices voted 8-3 on major changes to the long-standing universal hepatitis B birth-dose policy, introducing shared decision-making for infants born to...
The Advisory Committee on Immunization Practices has released its updates to the annual immunization schedules for 2023 that includes new sections on COVID-19 and polio vaccine recommendations.
Authors of a new study evaluated the impact of tenofovir disoproxil fumarate on outcomes of more than 1000 individuals with chronic hepatitis B virus infection with cirrhosis.
